Clinical Trials Logo

Filter by:
NCT ID: NCT05708066 Withdrawn - Anxiety Clinical Trials

Aromatherapy With Lavender as Anxiolysis Prior to Cataracts Surgery

Start date: January 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the validity of lavender aromatherapy as a method of anxiolysis prior to a cataract surgery, and to see if this effect will extend intraoperatively to minimize patients' intraoperative medication requirements. The study team plans on enrolling 186 participants. The investigator team hypothesizes that: 1. Participants will have a lower anxiety score after the intervention 2. Participants will require less intraoperative sedation medication compared to participants that did not have the lavender intervention. 3. A decrease in intraoperative medication requirements will lead to a faster discharge time

NCT ID: NCT05707702 Withdrawn - Clinical trials for Low-grade Oral Dysplasia

Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia

Start date: April 29, 2024
Phase: Phase 3
Study type: Interventional

There are limited evidence-based management options for patients with low-grade oral dysplasia. Despite the risk of malignant transformation, management is frequently limited to risk factor reduction (such as smoking cessation) and clinical surveillance. An intervention for low-grade oral dysplasia which could induce regression or decrease rates of malignant transformation has the potential to be a valuable preventative tool to reduce rates of oral cancer. The investigators will conduct a randomized clinical trial to investigate if the administration of a probiotic lozenge to patients with low-grade oral dysplasia result in decreased peri-tumoral inflammation as evidenced by impacts on populations of tumor-associated macrophages and tumor-infiltrating lymphocytes, and decreased dysbiosis at the disease site compared with the contralateral normal site. The investigators hypothesize that these changes may increase the rate of clinical regression of these lesions.

NCT ID: NCT05702385 Withdrawn - Pancreas Cancer Clinical Trials

Clinical Utility Study for Exo-PDAC

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This is a national-level research study of oncologists, interventional gastroenterologists, and primary care providers. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care indications.

NCT ID: NCT05700864 Withdrawn - Neuropathy Clinical Trials

NGF Treatment for Patients With Neuropathic Corneal Pain

Start date: November 1, 2022
Phase: Phase 1
Study type: Interventional

This prospective, single center, interventional, open-label, single arm, non-randomized trial seeks to investigate the efficacy of Oxervate® (cenergermin 0.002% eye drops) on ameliorating the signs and symptoms of neuropathic corneal pain (NCP). The study aims to enroll 28 subjects with NCP. All patients will be evaluated for clinical symptoms and signs of NCP, corneal staining and nerve regeneration (by IVCM) at Baseline (Visit 2) through the end of study (16 weeks post treatment).

NCT ID: NCT05700630 Withdrawn - HIV-1-infection Clinical Trials

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Start date: July 15, 2024
Phase: Phase 1
Study type: Interventional

This is a single center Phase I clinical trial of FT538 administered intravenously (IV) once every 14 days for 4 consecutive doses for the reduction of the HIV reservoir in lymphoid tissue of HIV-infected individuals receiving standard of care (SOC) antiretroviral therapy (ART). As this is an early 1st in human study and the 1st for HIV-infected individual, the safety of FT538 is confirmed prior to the addition of oral vorinostat to explore the concept of "Kick and Kill".

NCT ID: NCT05696964 Withdrawn - Clinical trials for Diabetes Mellitus, Type 2

Improving Relationships Using Motivational Interviewing

IRMIT
Start date: February 1, 2024
Phase: N/A
Study type: Interventional

This research aims to optimize patient-clinician relationships through motivational interviewing training in a Federally Qualified Health Center (FQHC) to improve health outcomes for African American patients with Type 2 diabetes.

NCT ID: NCT05693090 Withdrawn - NSCLC Clinical Trials

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Start date: February 1, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1a/b, multicenter, open-label, dose escalation (1a) and dose expansion (1b) study. The purpose of this study is to measure safety, tolerability, and preliminary efficacy with the combination of tipifarnib with osimertinib in patients with advanced/metastatic EGFR-mutated non-small cell lung cancer.

NCT ID: NCT05663554 Withdrawn - Obesity Clinical Trials

Improving Glycemic Control Using a Virtual Weight Control Program Among Adults With Type 2 Diabetes

VITAL-2
Start date: January 15, 2023
Phase: N/A
Study type: Interventional

The study is a randomized clinical trial with the primary aim of determining the effectiveness of the WW intervention at reducing HbA1c in patients with type 2 diabetes.

NCT ID: NCT05661669 Withdrawn - Clinical trials for Alcohol Use Disorder

Ketamine for the Treatment for Alcohol Use Disorder in the ED

Start date: October 25, 2023
Phase: Phase 2
Study type: Interventional

The investigators' approach is to conduct a pilot double-blind, placebo-controlled randomized clinical trial with individuals with alcohol use disorder (AUD) seeking inpatient alcohol detoxification in the emergency department (ED) to receive either intravenous ketamine or saline placebo. The primary aim is to evaluate the intervention's safety. The secondary aim is to evaluate the preliminary efficacy of alcohol-related outcomes.

NCT ID: NCT05661435 Withdrawn - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD

Start date: March 15, 2023
Phase:
Study type: Observational

Listening to breath sounds with the stethoscope/auscultation is used by pulmonary physicians in conjunction with pulmonary function, signs and symptoms, oxygen saturation and diagnostic testing to admit, follow and discharge patients from hospital. Of these, only auscultation routinely ceases upon discharge from Hospital. Healthcare utilization statistics have shown that for more than a decade, readmission after discharge for an exacerbation of COPD or severe asthma (or chronic heart failure) remains a major problem. The Strados RESP Biosensor has been designed to extend the range of lung sound recording both geographically and temporally to improve the standard of care when access to continuous monitoring has been replaced by periodic or no monitoring. The primary purpose of this study is to assess the associations between RESP Biosensor-acquired lung findings and subjective measures of respiratory symptoms as measured by validated measurement tools, and objective measure of respiratory physiology as determined by home spirometry